Cambridge's contractor market is anchored by deep technology and life sciences. The Silicon Fen cluster, spread across the Cambridge Science Park, the Biomedical Campus and a network of business and innovation parks, includes global semiconductor and software firms, major pharmaceutical and biotech companies, and a constant stream of university spinouts. This generates demand for highly specialised contractors: chip and hardware engineers, embedded and systems software developers, data scientists, and scientific, clinical and regulatory contractors in the pharma and biotech space. Where the end client is a large global firm or a major pharma company, off-payroll Chapter 10 applies and the client issues the status determination statement.
The distinctive Cambridge dynamic is the mix of client sizes. Alongside the multinationals sit many genuinely small spinouts and early-stage scale-ups. A small end client (meeting two of the £15m turnover, £7.5m balance sheet and 50 employees tests, and not in scope until 6 April 2027 even if it crosses them) keeps the status decision with the contractor under Chapter 8, where the PSC self-assesses and the 5% expenses allowance is still available. So a Cambridge contractor can genuinely be inside-IR35-determined by a large pharma client on one engagement and self-assessing as outside for a small spinout on another in the same tax year. Getting the regime right for each client is essential, and it is easy to get wrong.
The technical and scientific nature of Cambridge contracting also affects status. Genuine specialist expertise, autonomy over method, and being engaged for a defined deliverable point toward outside IR35, but long embedded engagements in a large client's R&D or clinical function raise the usual control and mutuality questions. We map each client to the correct regime, review contracts and working practices before you sign, check status determination statements for large clients, support the 45-day client-led disagreement process where an inside finding looks wrong, and model umbrella versus limited company honestly, flagging the April 2026 umbrella joint-and-several-liability change.